NEW YORK, Feb. 2, 2021
/PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the
"Company") today announced that Dr. Neil H. Bander, M.D., a
physician-researcher at Weill Cornell Medicine, has joined the
Company's Scientific Advisory Board.
"Dr. Bander heads one of the world's most experienced and
accomplished teams in antibody-targeted therapy of prostate cancer
at Cornell University and is a widely
respected inventor of patented technologies and recognized expert
in the field of urological oncology," commented Mr. Anthony Hayes, CEO of AIkido. "Importantly, Dr.
Bander is the inventor of targeted radiopharmaceutical therapy
technology at Convergent Therapeutics, Inc. which we are proud to
support. We are honored to have him join our team of advisors and
work more directly in our efforts to advance the development of
this technology."
"Using his clinical background and laboratory efforts, Dr.
Bander has exemplified the role of surgeon-scientist," added Mr.
Hayes. "His research has spawned novel clinical trials that are
unique in urological oncology and have already made a difference in
the lives of prostate cancer patients. We look forward to
leveraging his expertise as we continue to develop our platforms
and forge a path towards the treatment of cancer."
Dr. Bander, M.D. completed fellowship training in both tumor
immunology and urological oncology at Memorial Sloan-Kettering
Cancer Center in New York City.
Subsequently, at New York-Presbyterian Hospital-Weill Cornell
Medical Center (NYPH/WCM), where he is the Bernard and Josephine
Chaus Professor of Urologic Oncology, he has focused on clinical
urological oncology and the development of monoclonal antibodies
for targeted cancer therapy. As a result of his efforts, his
research group developed the first antibodies to prostate-specific
membrane antigen (PSMA) that could effectively bind prostate cancer
cells. As a result of his efforts, PSMA is now recognized as the
most prostate-cancer specific cell surface antigen known and is the
target of a wide variety of anti-cancer technologies. The NYPH/WCM
Uro-Oncology research team has sponsored more than 15 clinical
trials with anti-PSMA antibodies and more recently, small molecule
PSMA agents, in prostate cancer patients with more than 500
patients treated in these trials.
Dr. Bander said, "I look forward to joining my Weill-Cornell
colleague, Dr. Scott Tagawa, on
AIkido's SAB, as well as the other AIkido team members, to generate
advances that make an impactful difference in the lives of cancer
patients."
About AIkido Pharma Inc.
AIkido Pharma Inc. was
initially formed in 1967 and is a biotechnology company with a
diverse portfolio of small-molecule anti-cancer therapeutics.
The Company's platform consists of patented technology from leading
universities and researchers and we are currently in the process of
developing an innovative therapeutic drug platform through strong
partnerships with world renowned educational institutions,
including The University of Texas at Austin and Wake Forest
University. Our diverse pipeline of therapeutics includes therapies
for pancreatic cancer, acute myeloid leukemia (AML) and acute
lymphoblastic leukemia (ALL). In addition, we are constantly
seeking to grow our pipeline to treat unmet medical needs in
oncology. The Company is also developing a broad-spectrum
antiviral platform that may potentially inhibit replication of
multiple viruses including Influenza virus, SARS-CoV (coronavirus),
MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this
press release constitute "forward-looking statements" within the
meaning of the federal securities laws. Words such as "may,"
"might," "will," "should," "believe," "expect," "anticipate,"
"estimate," "continue," "predict," "forecast," "project," "plan,"
"intend" or similar expressions, or statements regarding intent,
belief, or current expectations, are forward-looking statements.
While the Company believes these forward-looking statements are
reasonable, undue reliance should not be placed on any such
forward-looking statements, which are based on information
available to us on the date of this release. These forward-looking
statements are based upon current estimates and assumptions and are
subject to various risks and uncertainties, including without
limitation those set forth in the Company's filings with the SEC,
not limited to Risk Factors relating to its business contained
therein. Thus, actual results could be materially different. The
Company expressly disclaims any obligation to update or alter
statements whether as a result of new information, future events or
otherwise, except as required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.:
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-adds-inventor-dr-neil-h-bander-md-to-scientific-advisory-board-301220019.html
SOURCE AIkido Pharma Inc.